tiprankstipranks
Advertisement
Advertisement

CMPX Stock Latest News

Compass Therapeutics Maintained at Buy as Analyst Cites Promising CTX-8371 Data and Reaffirms $24 Price Target
RatingsCompass Therapeutics Maintained at Buy as Analyst Cites Promising CTX-8371 Data and Reaffirms $24 Price Target
11d ago
CMPX
Compass Therapeutics: Buy Rating Reiterated as Clinical Progress Strengthens Approval Odds; $6 Price Target Maintained
PremiumRatings
Compass Therapeutics: Buy Rating Reiterated as Clinical Progress Strengthens Approval Odds; $6 Price Target Maintained
27d ago
CMPX
Compass Therapeutics reports Q1 EPS (10c), consensus (10c)
PremiumThe Fly
Compass Therapeutics reports Q1 EPS (10c), consensus (10c)
28d ago
CMPX
Micron initiated, Rambus downgraded: Wall Street’s top analyst calls
PremiumThe Fly
Micron initiated, Rambus downgraded: Wall Street’s top analyst calls
1M ago
MU
TU
Compass Therapeutics price target lowered to $7 from $13 at Canaccord
PremiumThe Fly
Compass Therapeutics price target lowered to $7 from $13 at Canaccord
1M ago
CMPX
Compass Therapeutics downgraded to Market Perform from Outperform at Raymond James
PremiumThe FlyCompass Therapeutics downgraded to Market Perform from Outperform at Raymond James
1M ago
CMPX
Compass Therapeutics price target lowered to $6 from $12 at Stifel
Premium
The Fly
Compass Therapeutics price target lowered to $6 from $12 at Stifel
1M ago
CMPX
Compass Therapeutics selloff ‘an over-reaction,’ says Jefferies
Premium
The Fly
Compass Therapeutics selloff ‘an over-reaction,’ says Jefferies
1M ago
CMPX
Leerink says Compass data supports path forward for tovecimig in 2L BTC
PremiumThe Fly
Leerink says Compass data supports path forward for tovecimig in 2L BTC
1M ago
CMPX
Midday Fly By: Verizon reports ‘beat and raise,’ Shell to acquire ARC
PremiumThe Fly
Midday Fly By: Verizon reports ‘beat and raise,’ Shell to acquire ARC
1M ago
VZ
WW
Analyst Maintains Buy on Tovecimig Developer, Sees PFS Strength Underappreciated and Keeps $24 Price Target Unchanged
PremiumRatings
Analyst Maintains Buy on Tovecimig Developer, Sees PFS Strength Underappreciated and Keeps $24 Price Target Unchanged
1M ago
CMPX
H.C. Wainwright keeps Buy rating on Compass Therapeutics after data
PremiumThe Fly
H.C. Wainwright keeps Buy rating on Compass Therapeutics after data
1M ago
CMPX
Buy Rating Reiterated on Compass Therapeutics as Tovecimig Combo Shows Strong PFS Benefit but OS Signal Clouded by Crossover Effects
PremiumRatingsBuy Rating Reiterated on Compass Therapeutics as Tovecimig Combo Shows Strong PFS Benefit but OS Signal Clouded by Crossover Effects
1M ago
CMPX
Morning Movers: Domino’s Pizza sinks following first quarter results
Premium
The Fly
Morning Movers: Domino’s Pizza sinks following first quarter results
1M ago
VZ
CPB
Compass Therapeutics Reports Positive Phase 2/3 BTC Results
Premium
Company Announcements
Compass Therapeutics Reports Positive Phase 2/3 BTC Results
1M ago
8K
CMPX
Compass Therapeutics reports additional COMPANION-002 study results
PremiumThe Fly
Compass Therapeutics reports additional COMPANION-002 study results
1M ago
CMPX
Compass Therapeutics (CMPX): Favorable Risk‑Reward Ahead of Pivotal Tovecimig Data in Biliary Tract Cancer
PremiumRatings
Compass Therapeutics (CMPX): Favorable Risk‑Reward Ahead of Pivotal Tovecimig Data in Biliary Tract Cancer
2M ago
CMPX
Buy Rating on Compass Therapeutics: Anticipating Pivotal Tovecimig Data as a Key Value Inflection Point in Advanced Biliary Tract Cancer
PremiumRatings
Buy Rating on Compass Therapeutics: Anticipating Pivotal Tovecimig Data as a Key Value Inflection Point in Advanced Biliary Tract Cancer
2M ago
CMPX
Compass Therapeutics reports Q4 EPS (9c), consensus (9c)
PremiumThe Fly
Compass Therapeutics reports Q4 EPS (9c), consensus (9c)
3M ago
CMPX
CMPX Upcoming Earnings Report: What to Expect?
PremiumPre-EarningsCMPX Upcoming Earnings Report: What to Expect?
3M ago
CMPX
Buy Rating on Tovecimig Driven by Early Efficacy Signals and Differentiated Risk–Benefit Profile in Biliary Tract Carcinoma
Premium
Ratings
Buy Rating on Tovecimig Driven by Early Efficacy Signals and Differentiated Risk–Benefit Profile in Biliary Tract Carcinoma
3M ago
CMPX
Compass Therapeutics Moves CTX-10726 Into the Clinic: What Early Investors Should Know
Premium
Company Announcements
Compass Therapeutics Moves CTX-10726 Into the Clinic: What Early Investors Should Know
3M ago
CMPX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >